Table 4.
Baseline symptoms, examination, and laboratory tests on the day of IV ribavirin initiation (day 0 ribavirin) in the 34 individuals in the treatment analysis cohort.
| Type | Clinical symptom or laboratory test | N (%) |
|---|---|---|
| General | Fever (≥100.5 °F.) | 26/33 (79%) |
| Headache | 18/25 (72%) | |
| Hypertension (diastolic >90 mmHg) | 6/34 (18%) | |
| Hypotension (systolic BP < 90 mm) | 2/34 (6%) | |
| Polyuria (>3 l/24 h) | 2/13 (6%) | |
| Oliguria (<400 cm3/24 h) | 1/34 (3%) | |
| Vascular instability or fragility | Conjunctival injection | 21/34 (62%) |
| Facial edema or flushing | 16/34 (47%) | |
| Petechiae | 6/34 (18%) | |
| Ecchymoses | 1/33 (3%) | |
| Bleeding | 1/33 (3%)a | |
| Severe hemorrhage (systolic BP <90 mm) | 0/33 (0%) | |
| Gastrointestinal | Pain in abdomen, back, or flank | 30/34 (88%) |
| Nausea and vomiting | 20/34 (59%) | |
| Diarrhea | 21/34 (62%) | |
| Laboratory | Increased AST (>46 U/ml) | 25/25 (100%) |
| Hypoalbuminemia (<3.9 g/dl) | 26/26 (100%) | |
| Thrombocytopenia (≤140,000 mm−3) | 32/34 (94%) | |
| Proteinuria (trace or greater) | 31/33 (94%) | |
| Decreased corrected calcium | 15/17 (88%) | |
| Increased ALT (>42 U/ml) | 21/25 (84%) | |
| Decreased total protein (<6.6 g/dl) | 18/20 (80%) | |
| Urine red blood cells | 23/32 (72%) | |
| Leukocytosis (>10,800 cells/mm3) | 21/34 (62%) | |
| PTT (>31.9 s) | 9/15 (60%) | |
| Increased creatinine (≥1.3 gm/dl) | 19/34 (56%) | |
| Decreased magnesium (<1.6 mmol/ml) | 4/9 (44%) | |
| Elevated uric acid (>7.2 mg/dl) | 4/15 (27%) | |
| Prothrombin time (>14.1 s) | 4/15 (27%) | |
| Increased lipase (>205 U/ml) | 3/14 (21%) | |
| Increased amylase (>88 U/ml) | 3/20 (15%) | |
| Increased total bilirubin (>1.3 mg/dl) | 3/30 (10%) | |
| Decreased hematocrit (<33%) | 2/34 (6%) | |
| Decreased WBC (<3500 cells/mm3) | 1/34 (3%) | |
BP = blood pressure; AST = aspartate aminotransferase; ALT = alanine aminotransferase; PTT = partial thromboplastin time; WBC = white blood cell count.
a
Epistaxis.